CoChat

Metformin and berberine, two versatile drugs in treatment of common metabolic diseases

Open access
Wang, Haoran, Zhu, Chen, Ying, Ying, Luo, Lingyu, Huang, Deqiang, Luo, Zhijun · 2018 · Oncotarget
Cited by 122

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

// Haoran Wang 1, * , Chen Zhu 1, * , Ying Ying 2 , Lingyu Luo 1 , Deqiang Huang 1 and Zhijun Luo 2, 3 1 Department of Gastroenterology, Research Institute of Digestive Diseases, The First Hospital of Nanchang University, Nanchang, China 2 Jiangxi Provincial Key Laboratory of Tumour Pathogenesis and Molecular Pathology, Department of Pathophysiology, School of Basic Medical Sciences, Nanchang University, Nanchang, China 3 Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA * These authors contributed equally to this work Correspondence to: Deqiang Huang, email: dqhuang0515@163.com Zhijun Luo, email: zluo@bu.edu Keywords: metformin, berberine, metabolic diseases, tumour Received: July 19, 2017 Accepted: August 17, 2017 Published: September 11, 2017 ABSTRACT Metformin has been used as a glucose lowering drug for several centuries and is now a first-line drug for type 2 diabetes mellitus (T2DM). Since the discovery that it activates AMP-activated protein kinase (AMPK) and reduces risk of cancer, metformin has drawn great attentions. Another drug, berberine, extracted from berberis vulgaris L. (root), was an ancient herbal medicine in treating diarrhea. Ongoing experimental and clinical studies have illuminated great potential of berberine in regulation of glucose and lipid homeostasis, cancer growth and inflammation. Furthermore, the lipid lowering effect of berberine is comparable to those conventional lipid drugs but with low toxicity. Therefore, it is right time to transform beneficial effects of berberine into therapeutic practice. Metformin and berberine share many features in actions despite different structure and both could be excellent drugs in treating T2DM, obesity, cardiac diseases, tumour, as well as inflammation. Since these disorders are often connected and comprise common pathogenic factors that could be targeted by the two drugs, understanding their actions can give us rationale for expansion of their clinical uses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.20807

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 122

Metadata

Authors
Wang, H., Zhu, C., Ying, Y., Luo, L., Huang, D., & Luo, Z.
Venue
Oncotarget
Published
2017-09-11
Volume
9
Issue
11
Pages
10135-10146
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2755712200
Cited by
122
References
24
FWCI
6.54
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.